Peter R Barker

US Patent:

6489369, Dec 3, 2002

Filed:

Jan 28, 2000

Appl. No.:

09/493359

Inventors:

Bruce H. Morimoto - Redwood City CA
Peter L. Barker - Pleasanton CA
Vincent Hernandez - Brookdale CA
Cass K. Piper - Redwood Shores CA

Assignee:

SuperGen, Inc. - San Ramon CA

International Classification:

A61K 31685

US Classification:

516170, 514171, 514 77, 514 78, 514182

Abstract:

A pharmaceutical formulation comprising a pharmaceutically active agent, which is insoluble or sparingly soluble in water and a sterol phosphocholine surfactant.

US Patent:

7060290, Jun 13, 2006

Filed:

Feb 16, 2000

Appl. No.:

09/890006

Inventors:

Bruce H. Morimoto - Redwood City CA, US
Peter L. Barker - Pleasanton CA, US

Assignee:

Supergen, Inc. - Dublin CA

International Classification:

A61K 9/127
A61K 31/665
A61K 31/675
A61K 31/685
C07D 259/00
C07D 487/22
C07F 9/02

US Classification:

424450, 514 78, 514 79, 514100, 540456, 540460, 540478, 544243, 544337, 546 23, 548113, 548119

Abstract:

Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstituted alkenyl, (iii) substituted or unsubstituted alkanoyl, (iv) substituted or unsubstituted alkenoyl wherein the double bond is cis, and (v) (ortho or para) carbonyl-substituted aryl; and wherein the subtituent is each an independent group or linked together thereby forming a ring; and wherein X is one or more substituted or unsubstituted group containing one or more O, N, or S atom and wherein the substituent is each an independent group or linked together thereby forming a ring; and wherein the therapeutic agent is an alcohol-containing water-insoluble steroids or another alcohol containing compounds and methods to prepare such compounds.

US Patent:

20060166903, Jul 27, 2006

Filed:

Mar 21, 2006

Appl. No.:

11/386991

Inventors:

Bruce Morimoto - Redwood City CA, US
Peter Barker - Pleasanton CA, US

Assignee:

Supergen Corporation - Dublin CA

International Classification:

C07J 17/00
A61K 31/66
C07J 51/00

US Classification:

514026000, 514114000, 514129000, 536006100, 552506000

Abstract:

Disclosed are compounds of general formula (I) that function as prodrugs, thereby increasing bioavailabilities of the linked therapeutic agents, wherein the LINKER is (i) substituted or unsubstituted alkyl, (ii) substituted or unsubstituted alkenyl, (iii) substituted or unsubstituted alkanoyl, (iv) substituted or unsubstituted alkenoyl wherein the double bond is cis, and (v) (ortho or para) carbonyl-substituted aryl; and wherein the substituent is each an independent group or linked together thereby forming a ring; and wherein X is one or more substituted or unsubstituted group containing one or more O, N, or S atom and wherein the substituent is each an independent group or linked together thereby forming a ring; and wherein the therapeutic agent is an alcohol-containing water-insoluble steroids or another alcohol containing compounds and methods to prepare such compounds.

US Patent:

20130046232, Feb 21, 2013

Filed:

Oct 16, 2012

Appl. No.:

13/652787

Inventors:

Zoll Circulation, Inc. - Sunnyvale CA, US
Scott M. Evans - Santa Ana CA, US
David P. Balding - Mission Viejo CA, US
Peter Barker - Oceanside CA, US

Assignee:

ZOLL CIRCULATION, INC. - Sunnyvale CA

International Classification:

A61F 7/12
A61M 5/44
A61M 1/00

US Classification:

604 28, 607106, 604508

Abstract:

A kit of parts comprises a system and instructions for use for controlling patient temperature which uses a central venous line catheter having a heat exchange element. The central venous line catheter is provided with one or more lumens for providing access to the central blood supply of the patient, and with additional lumens for communicating heat exchange fluid to the heat exchange element. Heat exchange fluid temperature is controlled through a feed back loop in which patient temperature is sensed and used to control a temperature control unit comprising a heating device and/or a cooling device in heat exchange relationship with the heat exchange fluid. A tubing set transports the heat exchange fluid between the central venous line and the temperature control unit, with a pump serving to circulate the fluid in a closed fluid circuit in the system.

US Patent:

20130227279, Aug 29, 2013

Filed:

Feb 28, 2013

Appl. No.:

13/780191

Inventors:

Good Technology Corporation - , US
Kevin Charles Lohman - Sunnyvale CA, US
Haniff Somani - Mercer Island WA, US
Peter Maximilian Barker - Flower Mound TX, US
Nicholas Benedict Van Someren - Atherton CA, US

Assignee:

Good Technology Corporation - Dover DE

International Classification:

H04L 29/06

US Classification:

713165

Abstract:

Data is stored on a computing device in an encrypted form using a control application. A data access application requests access to the data. It is determined whether the data access application has available a shared encryption key that is available to the control application. If a shared encryption key is available, the shared encryption key is used to encrypt a request for access to the data. If a shared encryption key is not available, a shared encryption key is negotiated with the control application, and the negotiated shared encryption key is used to encrypt the request for access to the data. The control application receives the encrypted request, decrypts the encrypted request using the shared encryption key, and makes the data stored on the computing device in encrypted form available to the data access application in response to the decrypted request.

US Patent:

20130227280, Aug 29, 2013

Filed:

Feb 28, 2013

Appl. No.:

13/780283

Inventors:

Good Technology Corporation - , US
Kevin Charles LOHMAN - Sunnyvale CA, US
Haniff SOMANI - Mercer Island WA, US
Peter Maximilian BARKER - Flower Mound TX, US

Assignee:

Good Technology Corporation - Dover DE

International Classification:

H04L 9/08

US Classification:

713165

Abstract:

A data access application key is generated. The data access application key is for use by a data access application to enable decryption of data that is stored in encrypted form on a computing device using the data access application key. The data access application key is generated using an identifier of the data access application and an application key that is specific to at least one of the computing device and/or a user of the computing device.

US Patent:

20130227287, Aug 29, 2013

Filed:

Feb 28, 2013

Appl. No.:

13/780245

Inventors:

Good Technology Corporation - , US
Kevin Charles Lohman - Sunnyvale CA, US
Haniff Somani - Mercer Island WA, US
Peter Maximilian Barker - Flower Mound TX, US

Assignee:

Good Technology Corporation - Dover DE

International Classification:

H04L 29/08

US Classification:

713168, 709201

Abstract:

Data is stored on a computing device in encrypted form in respective digital containers. At least one data access application is stored on the computing device. A control application of the computing device connects to a remote control center. A command from the remote control center is received at the connected control application. The command contains an action to be taken in respect of at least one of the at least one data access application and the containers stored on the computing device. The command is passed from the connected control application to the data access application or container, and the data access application or container carries out the command.

US Patent:

52506797, Oct 5, 1993

Filed:

Apr 10, 1992

Appl. No.:

7/866931

Inventors:

Brent Blackburn - San Francisco CA
Robert McDowell - San Francisco CA
Thomas Gadek - Oakland CA
Peter Barker - El Granada CA
Lawrence McGee - Pacifica CA
Rob Webb - Moss Beach CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07D26114
A61K 3155

US Classification:

540490

Abstract:

A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII. sub. b III. sub. a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.